These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

504 related items for PubMed ID: 9350175

  • 21. Activated protein C resistance and the FV:R506Q mutation in a random population sample--associations with cardiovascular risk factors and coagulation variables.
    Lowe GD, Rumley A, Woodward M, Reid E, Rumley J.
    Thromb Haemost; 1999 Jun; 81(6):918-24. PubMed ID: 10404768
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families?
    Koeleman BP, van Rumpt D, Hamulyák K, Reitsma PH, Bertina RM.
    Thromb Haemost; 1995 Aug; 74(2):580-3. PubMed ID: 8584987
    [Abstract] [Full Text] [Related]

  • 25. [Resistance to activated protein C. The most common cause of familial thrombophilia].
    Larsen TB, Ravn HB, Lassen JF, Lund ED, Brandslund I.
    Ugeskr Laeger; 1996 Nov 11; 158(46):6584-8. PubMed ID: 8966822
    [Abstract] [Full Text] [Related]

  • 26. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
    Curvers J, Thomassen MC, Rimmer J, Hamulyak K, van der Meer J, Tans G, Preston FE, Rosing J.
    Thromb Haemost; 2002 Jul 11; 88(1):5-11. PubMed ID: 12152677
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Inherited resistance to activated protein C caused by presence of the FV:Q506 allele as a basis of venous thrombosis.
    Dahlbäck B, Zöller B, Hillarp A.
    Haemostasis; 1996 Oct 11; 26 Suppl 4():301-14. PubMed ID: 8979136
    [Abstract] [Full Text] [Related]

  • 29. [Activated C protein resistance: laboratory study and prevalence of the defect in the Chilean population].
    Pereira J, Quiroga T, Goycoolea M, Muñoz B, Hidalgo P, Kaltwasser G, Mezzano D.
    Rev Med Chil; 1996 Jun 11; 124(6):663-8. PubMed ID: 9041721
    [Abstract] [Full Text] [Related]

  • 30. Laboratory diagnosis of hereditary thrombophilia.
    Michiels JJ, Hamulyák K.
    Semin Thromb Hemost; 1998 Jun 11; 24(4):309-20. PubMed ID: 9763348
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Activated protein C resistance--a recently discovered hereditary thrombophilia].
    Moland L, Sandset PM.
    Tidsskr Nor Laegeforen; 1998 Sep 30; 118(23):3590-5. PubMed ID: 9820002
    [Abstract] [Full Text] [Related]

  • 33. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.
    De Mitrio V, Marino R, Scaraggi FA, Di Bari L, Giannoccaro F, Petronelli M, Ranieri P, Tannoia N, Schiraldi O.
    Blood Coagul Fibrinolysis; 1999 Oct 30; 10(7):409-16. PubMed ID: 10695766
    [Abstract] [Full Text] [Related]

  • 34. Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease.
    Zöller B, He X, Dahlbäck B.
    Thromb Haemost; 1995 May 30; 73(5):743-5. PubMed ID: 7482396
    [Abstract] [Full Text] [Related]

  • 35. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.
    Zöller B, Svensson PJ, He X, Dahlbäck B.
    J Clin Invest; 1994 Dec 30; 94(6):2521-4. PubMed ID: 7989612
    [Abstract] [Full Text] [Related]

  • 36. Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation.
    Tans G, Nicolaes GA, Rosing J.
    Semin Hematol; 1997 Jul 30; 34(3):244-55. PubMed ID: 9241709
    [Abstract] [Full Text] [Related]

  • 37. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
    Guasch JF, Lensen RP, Bertina RM.
    Thromb Haemost; 1997 Feb 30; 77(2):252-7. PubMed ID: 9157576
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients.
    Montes MA, Fox EA, Longtine JA, Dorfman DM.
    Arch Pathol Lab Med; 1998 Apr 30; 122(4):325-9. PubMed ID: 9648899
    [Abstract] [Full Text] [Related]

  • 40. Activated protein C resistance in anterior ischaemic optic neuropathy.
    Nagy V, Facsko A, Takacs L, Balazs E, Berta A, Balogh I, Edes I, Czuriga I, Pfliegler G.
    Acta Ophthalmol Scand; 2004 Apr 30; 82(2):140-3. PubMed ID: 15043529
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.